Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or Dabigatran-Reference-Cited by-同舟云学术

Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or Dabigatran

Published:2018-03-27 Issue:7 Volume:63 Page:1878-1889
ISSN:0163-2116
Container-title:Digestive Diseases and Sciences
language:en
Short-container-title:Dig Dis Sci

Author:

Kolb Jennifer M.,Flack Kathryn Friedman,Chatterjee-Murphy Prapti,Desai Jay,Wallentin Lars C.,Ezekowitz Michael,Connolly Stuart,Reilly Paul,Brueckmann Martina,Ilgenfritz John,Aisenberg James

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Physiology

Link

http://link.springer.com/article/10.1007/s10620-018-5007-6/fulltext.html

Reference26 articles.

1. Sherwood MW, Douketis JD, Patel MR, et al. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular. Circulation. 2014;129:1850–1859.

2. Michaels LBR. Relapses of thromboembolic disease after discontinued anticoagulant therapy. A comparison of the incidence after abrupt and after gradual termination of treatment. Am J Cardiol. 1967;20:670–673.

3. Landefeld CS, Rosenblatt MW, Goldman L. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. Am J Med. 1989;87:153–159.

4. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;17:1139–1151.

5. Flack KF, Desai J, Kolb JM, et al. Major gastrointestinal bleeding often is caused by occult malignancy in patients receiving warfarin or dabigatran atrial fibrillation. Clin Gastroenterol Hepatol. 2017;15:682–690.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk factors for anticoagulant-associated gastrointestinal hemorrhage: a systematic review and meta-analysis;The Korean Journal of Internal Medicine;2024-01-01

2. A review on increasing risk for gastrointestinal bleeding associated with dabigatran;Signa Vitae;2024

3. A new model to predict the risk of major gastrointestinal bleeding in patients on direct oral anticoagulants (dabigatran and rivaroxaban);British Journal of Clinical Pharmacology;2022-08-22

4. Intestinal Tuberculosis Presenting with Gastrointestinal Bleeding in Patient on Warfarin Therapy;Case Reports in Gastrointestinal Medicine;2022-05-14

5. Restarting Warfarin vs Direct Oral Anticoagulants After Major Gastrointestinal Bleeding and Associated Outcomes in Atrial Fibrillation: A Cohort Study;Clinical Gastroenterology and Hepatology;2022-02